Total Participants: 3389

- Delegates 79%
- Exhibitors 8%
- Students 5%
- Invited speakers 5%
- Media 2%
- Fellowship, VIP and guests 1%
Scientific Programme Related Statistics

<table>
<thead>
<tr>
<th>Abstracts submitted at general deadline</th>
<th>Oral Presentations</th>
<th>Poster Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>593</td>
<td>29</td>
<td>472</td>
</tr>
</tbody>
</table>

Poster Discussion

<table>
<thead>
<tr>
<th>Abstracts submitted at late-breaking deadline</th>
<th>Late-breaking abstracts selected</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>8</td>
</tr>
</tbody>
</table>

Total Abstracts Submitted: 593

Abstract Topics

- Surgery 23%
- Pathology and Molecular Pathology 12%
- Detection, Diagnosis and Imaging 11%
- Epidemiology, Prevention, Screening 11%
- Adjuvant Drug Therapy 9%
- Radiotherapy 7%
- Metastatic Drug Therapy 7%
- Basic Science 6%
- Nursing, Supportive Care 5%
- Others 5%
- Education and Advocacy 4%
Top 10 Abstract Submission by Country (Top 10)

Total Abstracts Submitted: **593**

- **UK 14%**
- **The Netherlands 11%**
- **Japan 10%**
- **India 5%**
- **Italy 5%**
- **Korea 4%**
- **Germany 3%**
- **Spain 3%**
- **Belgium 3%**
- **France 3%**
- **Others 39%**
Top 10 Countries by Participation

- United Kingdom: 16%
- The Netherlands: 9%
- Switzerland: 6%
- USA: 4%
- Belgium: 4%
- China: 4%
- Italy: 4%
- Austria: 3%
- Japan: 3%
- Sweden: 3%
- Others: 44%

% of total attendance

Continent Overview

- Europe: 69%
- Asia: 14%
- Americas: 9%
- Middle East: 5%
- Australasia: 2%
- Africa: 1%

% of total attendance
Place of Work

- Regulatory Authorities 1%
- Regulatory Affairs 1%
- Professional Society 1%
- Contract Research Organisation 1%
- Government 1%
- Academia 1%
- University 2%
- Pharma Industry 2%
- Non-Profit Organisation 2%
- Private Practice 2%
- Cancer Research Centre 3%
- Industry 6%
- Hospital/Clinic 9%
- University Hospital 11%
- Cancer Centre 12%
- General Hospital 16%

% of total attendance (excluding group registrations)
Profession

- Neuro-Surgeon <1%
- Neurologist <1%
- Paediatric Oncologist <1%
- Palliative Care Specialist <1%
- Nuclear Medicine <1%
- Physiotherapist <1%
- Regulatory Affairs <1%
- Community Pharmacist <1%
- Policy Maker <1%
- Clinical Pharmacist <1%
- Haematologist <1%
- Pharmacologist <1%
- Psychologist <1%
- Geneticist <1%
- General Practitioner (GP) <1%
- Hospital Pharmacist <1%
- Young Oncologist <1%
- Clinical Trial Coordinator <1%
- Oncology Pharmacist <1%
- Statistician <1%
- Translational Scientist <1%
- Pathologist 1%
- Patient Advocate 1%
- Radiation Oncologist 1%
- Basic Scientist 2%
- Medical Affairs 2%
- Student 2%
- Gynaecologist 2%
- Radiologist 2%
- Radiotherapist 2%
- Nurse 4%
- Clinical Oncologist 6%
- Surgeon 6%
- General Surgeon 9%
- Medical Oncologist 9%
- Surgical Oncologist 12%

% of all delegates (excluding group registrations)
**App and Online Statistics**

**App Facts**
- Total Downloads: **1276**
- Android: 17%
- Ipad: 37%
- Iphone: 46%

**Website**

**EBCC9 page views**
- Total number of page views: **395,596**
- Webcasts and video views: **6,802**

**Tweets**
- EBCC9 Tweets: **1,068**
- Accounts tweeting using #EBCC9: **369**

**#EBCC9 Impressions**: **4,358,890**

Most popular sessions visited
1. Opening Symposium
2. Highlights in Benign and Pre-Invasive Breast Disease
3. Management of the Axilla – Ensuring Best Practice Today